Bausch Health Companies (BHC) PT Raised to $30 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Bausch Health Companies Inc. Announces Second-Quarter 2018 Results
August 7, 2018 7:00 AM EDTLAVAL, Quebec, Aug. 7, 2018 /PRNewswire/ --
Second-Quarter 2018 Financial Results Revenues of $2.128 Billion GAAP Net Loss of $873 Million GAAP Cash Flow from Operations of $222 Million Adjusted EBITDA (non-GAAP)1 of $868 Million Delivered Second Consecutive Quarter of Overall Organic Revenue Growth2, Driven by the Salix and Bausch + Lomb/International Segments3 XIFAXAN® Revenue Increased by 26% Compared to the Second Quarter of 2017 Maintained Revenue Guidance Range and Raised Full-Year Adjusted EBITDA (non-GAAP) Guidance RangeBausch Health Companies... More
